Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling

Authors:

Abstract
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
Funding Information
  • Eshelman Innovation
  • Allergopharma
  • Novartis Pharma
  • Wellcome Trust (106169/ZZ14/Z)
  • Wellcome Trust (095751/Z/11/Z)
  • Wellcome Trust (102894/Z/13/Z)
  • Takeda Pharmaceutical Company
  • Forskerakademiet
  • Ministerstvo Vnitra České Republiky (18‐24070Y)
  • European Molecular Biology Organization
  • Ludwig Institute for Cancer Research
  • AbbVie
  • Bayer
  • Boehringer Ingelheim
  • Canada Foundation for Innovation
  • Genome Canada
  • Erzincan Üniversitesi (ULTRA‐DD 115766)
  • Janssen
  • Meso Scale Diagnostics
  • Ontario Ministry of Economic Development and Innovation
  • Pfizer
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Myeloma UK
  • American Heart Association (15GRNT22970025)
  • National Institutes of Health (R01CA190542)
  • National Institutes of Health (R21AI124049)

This publication has 67 references indexed in Scilit: